Illumina, Inc. (ILMN) Director Jay T. Flatley Sells 2,540 Shares
Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 2,540 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $197.39, for a total value of $501,370.60. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at $106,427,950.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Illumina, Inc. (NASDAQ ILMN) traded up 2.23% on Thursday, hitting $204.20. The company had a trading volume of 814,776 shares. The firm’s 50 day moving average price is $183.92 and its 200-day moving average price is $176.00. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $205.21. The stock has a market capitalization of $29.81 billion, a PE ratio of 40.97 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. During the same period last year, the business posted $0.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/31/illumina-inc-ilmn-director-jay-t-flatley-sells-2540-shares.html.
A number of hedge funds have recently modified their holdings of ILMN. Lord Abbett & CO. LLC increased its stake in shares of Illumina by 32.1% in the second quarter. Lord Abbett & CO. LLC now owns 87,926 shares of the life sciences company’s stock valued at $15,257,000 after buying an additional 21,347 shares in the last quarter. USA Financial Portformulas Corp acquired a new stake in shares of Illumina during the second quarter valued at approximately $2,674,000. Toronto Dominion Bank increased its stake in shares of Illumina by 25.3% in the second quarter. Toronto Dominion Bank now owns 49,462 shares of the life sciences company’s stock valued at $8,581,000 after buying an additional 9,976 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in shares of Illumina during the second quarter valued at approximately $15,049,000. Institutional investors and hedge funds own 93.32% of the company’s stock.
A number of equities analysts have recently issued reports on the company. Barclays PLC restated an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, August 9th. Vetr upgraded Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective for the company in a research report on Wednesday, August 9th. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Cowen and Company reiterated an “outperform” rating and issued a $200.00 target price on shares of Illumina in a report on Wednesday, August 2nd. Finally, Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $177.01.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.